Stille AB (STIL.ST)
SEK 217.0
(-0.46%)
SEK 217.0
(-0.46%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 66.55 Million SEK | 13.03% |
| 2022 | 58.88 Million SEK | -1.04% |
| 2021 | 59.5 Million SEK | 39.56% |
| 2020 | 42.63 Million SEK | -19.9% |
| 2019 | 53.22 Million SEK | 18.57% |
| 2018 | 44.89 Million SEK | 67.18% |
| 2017 | 26.85 Million SEK | 43.21% |
| 2016 | 18.75 Million SEK | -1.09% |
| 2015 | 18.95 Million SEK | 17.01% |
| 2014 | 16.2 Million SEK | 10.45% |
| 2013 | 14.66 Million SEK | -12.74% |
| 2012 | 16.8 Million SEK | -23.65% |
| 2011 | 22.01 Million SEK | 25.35% |
| 2010 | 17.56 Million SEK | -5.09% |
| 2009 | 18.5 Million SEK | 18.07% |
| 2008 | 15.67 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 172.41 Million SEK | 5.11% |
| 2024 Q2 | 164.02 Million SEK | 3.04% |
| 2024 Q1 | 159.19 Million SEK | 139.2% |
| 2023 Q3 | 64.02 Million SEK | 1.22% |
| 2023 Q1 | 59.07 Million SEK | 0.33% |
| 2023 Q4 | 66.55 Million SEK | 3.94% |
| 2023 Q2 | 63.25 Million SEK | 7.08% |
| 2023 FY | 66.55 Million SEK | 13.03% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | 58.88 Million SEK | 0.0% |
| 2022 Q1 | - SEK | -100.0% |
| 2022 FY | 58.88 Million SEK | -1.04% |
| 2021 FY | 59.5 Million SEK | 39.56% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q4 | 59.5 Million SEK | 0.0% |
| 2020 FY | 42.63 Million SEK | -19.9% |
| 2020 Q4 | 42.63 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | 53.22 Million SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 FY | 53.22 Million SEK | 18.57% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 FY | 44.89 Million SEK | 67.18% |
| 2018 Q4 | 44.89 Million SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | 53.97 Million SEK | 101.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 FY | 26.85 Million SEK | 43.21% |
| 2017 Q4 | 26.85 Million SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 18.75 Million SEK | -1.09% |
| 2016 Q4 | 18.75 Million SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 18.95 Million SEK | 17.01% |
| 2015 Q4 | 18.95 Million SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q3 | 16.57 Million SEK | -3.68% |
| 2014 Q2 | 17.2 Million SEK | 18.02% |
| 2014 Q1 | 14.58 Million SEK | -0.6% |
| 2014 FY | 16.2 Million SEK | 10.45% |
| 2014 Q4 | 16.2 Million SEK | -2.25% |
| 2013 Q2 | 14.71 Million SEK | -8.05% |
| 2013 Q1 | 16 Million SEK | -4.81% |
| 2013 FY | 14.66 Million SEK | -12.74% |
| 2013 Q3 | 14.46 Million SEK | -1.68% |
| 2013 Q4 | 14.66 Million SEK | 1.4% |
| 2012 Q2 | 19.28 Million SEK | -10.86% |
| 2012 Q1 | 21.63 Million SEK | -1.73% |
| 2012 Q3 | 14.54 Million SEK | -24.58% |
| 2012 Q4 | 16.8 Million SEK | 15.56% |
| 2012 FY | 16.8 Million SEK | -23.65% |
| 2011 Q2 | 17.91 Million SEK | 2.6% |
| 2011 Q1 | 17.45 Million SEK | -0.6% |
| 2011 FY | 22.01 Million SEK | 25.35% |
| 2011 Q3 | 18.31 Million SEK | 2.25% |
| 2011 Q4 | 22.01 Million SEK | 20.21% |
| 2010 Q1 | 21.6 Million SEK | 16.73% |
| 2010 FY | 17.56 Million SEK | -5.09% |
| 2010 Q4 | 17.56 Million SEK | -1.18% |
| 2010 Q3 | 17.77 Million SEK | -16.08% |
| 2010 Q2 | 21.17 Million SEK | -1.96% |
| 2009 FY | 18.5 Million SEK | 18.07% |
| 2009 Q4 | 18.5 Million SEK | 0.0% |
| 2009 Q2 | 19.48 Million SEK | -4.26% |
| 2009 Q1 | 20.35 Million SEK | 0.0% |
| 2008 FY | 15.67 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -873.139% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 45.088% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 45.088% |
| Arcoma AB | 28.02 Million SEK | -137.46% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | -124.492% |
| BICO Group AB (publ) | 493.1 Million SEK | 86.503% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | -6.655% |
| CellaVision AB (publ) | 126.03 Million SEK | 47.196% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -988.357% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -3658.101% |
| C-Rad AB (publ) | 64.09 Million SEK | -3.827% |
| Duearity AB (publ) | 4.15 Million SEK | -1500.216% |
| Dignitana AB (publ) | 7.41 Million SEK | -797.788% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -1698.73% |
| Getinge AB (publ) | 6.41 Billion SEK | 98.963% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 4053.555% |
| Iconovo AB (publ) | -4.86 Million SEK | 1468.84% |
| Integrum AB (publ) | 22.36 Million SEK | -197.617% |
| Luxbright AB (publ) | 8000.00 SEK | -831812.5% |
| Mentice AB (publ) | 14.1 Million SEK | -371.873% |
| OssDsign AB (publ) | 4.3 Million SEK | -1446.306% |
| Paxman AB (publ) | 19.99 Million SEK | -232.782% |
| Promimic AB (publ) | 330 Thousand SEK | -20067.576% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -812.685% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -458.377% |
| ScandiDos AB (publ) | 22.69 Million SEK | -193.314% |
| Sectra AB (publ) | 36.59 Million SEK | -81.888% |
| Sedana Medical AB (publ) | 42.97 Million SEK | -54.864% |
| Senzime AB (publ) | 20.34 Million SEK | -227.203% |
| SpectraCure AB (publ) | 1.00 SEK | -6655299900.0% |
| Vitrolife AB (publ) | 413 Million SEK | 83.885% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 53.001% |